The PanHellenic Institute of Neurodegenerative Diseases in cooperation with the Greek Association of Alzheimer’s Disease and Related Disorders organized the 8th National Scientific Congress of the greek Association of Alzheimer’s Disease and Related Disorders the period 28 February-3 March 2013 in Thessaloniki (Grand Hotel Palace).

The conference objective was to record the latest developments in the field of Dementia by bringing in direct contact scientists from across the world and consequently allow the exchange of experience for the update of the health care professionals along with all the other concerned groups for the very serious medically but also socially subject of Dementia.

ΙΑSIS PHARMA warmly supported this effort and there was a strong interest by the medical community for three of the most important neurological products of the company, namely Referan®, Sopalamin® 3B and Gabantin®.

Referan®, aniracetam (in the form of tabs and sachets), is an original product αποτελεί indicated from mild Dementia that improves the symptoms of brain atrophy in the elderly that are expressed as a cognitive deficit. Sopalamin 3B is a combination of 3 vitamins (B1, B6, B12) in a novel pharmaceutical form of double core tablets. Gabantin, gabapentin, is the first gabapentin generic launched in Greece and is indicated as an adjunctive treatment for epileptic seizures and as a treatment for peripheral neuropathic pain.